key: cord-0961941-zqm665gj authors: Fabi, Marianna; Guida, Fiorentina; Pierantoni, Luca; Greco, Laura; di Luca, Daniela; Lanari, Marcello title: Severe rhabdomyolysis in a child with Multisystem Inflammatory Syndrome (MIS-C): an autoimmune mechanism? date: 2021-08-08 journal: Pediatr Neurol DOI: 10.1016/j.pediatrneurol.2021.07.015 sha: 7043a563f2e97b842879538d845a17ba198775bd doc_id: 961941 cord_uid: zqm665gj nan To the Editor, Coronavirus disease 2019 (COVID-19) related myositis has been described as an initial presentation and a potential late complication of COVID-19 in adults 1 . To our knowledge, In children rhabdomyolysis has been extremely rare during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 2,3 without any detectable alteration in renal function nor signs of multiorgan involvement. We here describe the first case of rhabdomyolysis during multisystem inflammatory syndrome temporally related to COVID-19 (MIS-C). A 6 years-old African girl previously healthy was admitted for prominent abdominal pain with diarrhea, right chest pain, severe asthenia, and gait abnormality, diffuse and severe myalgia especially in lower limbs accentuated by muscles compression. The patient appeared exhausted and was febrile, tachypneic, oliguric, with a distended and tender abdomen and decreased breath sounds in the right lung base. The patient was appeared exhausted prostrate, febrile, tachypneic, oliguric, with a distended and tender abdomen. Breath sound was decreased at the right base. Cardiac auscultation and blood pressure were normal. Blood tests (Table 1) Peripheral blood smear showed rare schistocytes. Urine tests were normal and urine myoglobin was not detected. Blood cultures were negative, as well as molecular assays for Influenza, Enterovirus, Epstein-Barr Virus and Herpes Simplex in respiratory specimens. Chest-x ray revealed pneumonia in the right lower lobe with moderate pleural effusion. Abdominal ultrasound (US) showed thickening of the bowel wall with mild free abdominal effusion. Echocardiography excluded pathological findings. Echocardiography was without pathological findings. In the initial suspect of Hemolytic-uremic syndrome, Hemolytic-uremic syndrome was suspected so hyperhydration and antibiotic treatment were started. Reverse transcriptasepolymerase chain reaction nasopharyngeal swab resulted positive for SARS-CoV-2 infection. Since the evidence of COVID-19, a remarkable elevated. Based on elevated inflammatory markers, evidence of coagulopathy, acute gastrointestinal involvement and myocardial injury in SARS-CoV-2 infection, MIS-C was diagnosed. She received intravenous immunoglobulins (IVIG) 2g/kg and steroids (dexamethasone 0.2 mg/kg). Hypoalbuminemia led to fluid overload after IVIG administration and was treated with furosemide. Furosemide was administered to manage fluid imbalance secondary to volume overload IVIG-related during and hypoalbuminemia. After 6 hours, urinary output and renal function improved. She continued to experience myalgia and profound asthenia for 3 days, while CK level gradually reduced over time along with CRP ( Figure 1, top panel, a) . On day 3, Markers of myocardial injury increased over days and peaked later (respectively brain natriuretic peptide: 1385 pg/ml on day 4, and troponin I: 111.6 ng/l on day 5) (Figure 1, bottom panel, b) without evidence of ventricular dysfunction. On day 4 renal function and urine output normalized and patient's muscle pain decreased. Her laboratory tests had all normalized on the 15 th day following fever onset, and she was discharged. She was discharged complete normalization of laboratory tests on day 15 after fever onset. SARS-CoV-2 has been demonstrated to bind angiotensin-converting enzyme 2 receptor expressed on skeletal muscle and to cause renin-angiotensin downregulation directly affecting muscular integrity. Interestingly, some patient with COVID-19 related myositis presented with acute onset of severe muscle weakness, very high CK levels, associated to increased elevated inflammatory markers and clinical improvement after IVIG. These features highly resemble resembled necrotizing autoimmune myositis (NAM), an inflammatory myopathy that has been described after viral infections 4 . We hypothesize that SARS-CoV-2 could act as a trigger for myositis, inducing an immune T cell or macrophage-mediated response rather than a direct virus-induced cytotoxic damage, similarly to what was documented in the myocardium of adults with severe COVID-19 and in children with MIS-C 5 . In our patient markers of muscular damage seemed to reflect systemic inflammation rather than myocardial injury, thus indicating the skeletal muscle as a possible target of MIS-C. In our patient hyperCKemia was directly related to systemic inflammation, thus suggesting that skeletal muscle could represent another target of MIS-C. Secondly, myalgia and hyperCKemia CK levels significantly improved after the administration of IVIG and steroids, potentially suggesting an immune-mediated mechanism similarly to the cases of necrotizing autoimmune myositis (NAM) described for adults. A dysregulation of the immune system and an hyperinflammatory response have been widely reported as mechanisms in the pathogenesis of MIS-C. Several autoantibodies J o u r n a l P r e -p r o o f against proteins involved in immune cell signaling, structural proteins of myocytes and endothelial cells have been found, supporting an autoimmune mechanism in the pathogenesis of cardiovascular manifestations 6 . The response to immunomodulating treatment could strengthen this hypothesis. Therefore, we hypothesize a similar mechanism acting in the skeletal muscle, highlighting awareness of this possible condition in children with MIS-C and the need to monitor CK levels. ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Neuromuscular presentations in patients with COVID-19 Pediatric COVID-19-associated rhabdomyolysis: a case report Rhabdomyolysis as the Initial Presentation of SARS-CoV-2 in an Adolescent Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19